Objective — to study the restorative effect of immunoglobulin G (IgG) in patients on indicators of cellular immunity in patients with drug-resistant tuberculosis (DR-TB)/HIV co-infection at the level of CD4+ lymphocytes from 200 to 50 cells/μL. Materials and methods. The study involved 52 patients aged 20 to 55 years, the average age was (37.2 ± 7.8) years. All patients were HIV-positive with laboratory-confirmed DR-TB with mycobacterium resistance to first- and second-line drugs. Patients on DR-TB/HIV were divided as follows: Group 1 (cont­rol) — 26 patients with DR-TB/HIV with the CD4 lymphocyte count from 200 to 50 cells/μL, who received standard treatment with second-line antimycobacterial therapy (AMBT) and antiretroviral therapy (ARVT); Group 2 (basic) — 26 patients with DR-TB/HIV with a CD4 lymphocyte count from 200 to 50 cells/μL, who also received standard treatment of second-line AMBD and ARVT, with the addition of complex therapy with intravenous IgG. Results and discussion. In patients of Group 2, at the end of the 20th month of treatment, the normalization of T-helpers level was noted in 69.2 % of people, which reached the average values of (830.0 ± 15.2) cells/μL, with an increase to a subnormal level (408,0 ± 1.6) cells/μL in 30.8 % of patients (p < 0.05). Normalization of the T-helpers indicator in Group 1 was noted on the 20th month only in 42.3 % of people, and it amounted to (670.0 ± 14.5) cells/μL (р < 0.05). The relative (percentage) level of the T-helpers indicator in the 20th month reached normal values in 61.5 % (р < 0.05) of patients of Group 2, among patients of Group 1 — in 34.6 % of people (р < 0.05 ). The absolute number of T-suppressors at the end of the 20th month decreased to the norm in 76.9 % of patients and 46.2 % of patients in Groups 2 and 1, respectively (p < 0.05). In patients of Group 2, on the 20th month of treatment, the physiological level of the T-suppressors indicator (19—35) % was reached in 65.4 % of cases (р < 0.05); in Group 1, the normal level was registered in 38.5 % of patients (p < 0.05). The CD4+/CD8+ Ratio was below the norm in 100 % of patients of Group 1 during 14 months inclusive, and only on the 20th month it reached the norm in 23.1 % of patients (p < 0.05). Group 2 patients had normalization in 57.7 % of cases at the 20th month (р < 0.05). Conclusions. The additional use of intravenous IgG in the complex treatment of patients with DR-TB/HIV contributed to a faster recovery of the cellular link of immunity, which makes it possible to prescribe antiretroviral therapy to patients with DR-TB/HIV at an earlier time, prevent the development of systemic inflammation and improve the prognosis for survival.

No abstract

No abstract

No abstract

No abstract